Sucampo Reports Data - Analyst Blog
December 26 2013 - 5:00PM
Zacks
Sucampo Pharmaceuticals,
Inc. (SCMP) announced results from a phase IIa proof of
concept study for the evaluation of an intravenously administered
compound from the company’s ion channel activator program in lumbar
spinal stenosis (LSS) patients.
This multicenter, randomized,
double-blind, placebo-controlled, dose-escalation study
administered patients with 30 mcg or 60 mcg of the ion channel
activator or placebo twice daily for two weeks. Data from the study
revealed that patients receiving the ion channel activator
experienced a statistically significant improvement in pain as
compared to placebo.
The study also showed improvements
(though not statistically significant) in the primary and other
efficacy measures, including pain associated with quality of life
measures for patients treated with the ion channel activator.
In this study the ion channel
activator was well tolerated. On the basis of the findings from
this study, Sucampo intends to initiate an additional phase IIa
study in 2014 to identify the apt endpoints and dosing regimen for
the compound.
Last week, Sucampo commenced a
global, pivotal phase III program for Amitiza in pediatric
functional constipation. The phase III program comprises two
similarly designed, well-controlled pivotal studies. The first part
of the study, which has already commenced, is a randomized,
placebo-controlled, double-blind study which evaluates the
efficacy, safety and pharmacokinetics of Amitiza in pediatrics aged
6 to 17 years. The other part will evaluate Amitiza liquid
formulation in patients aged 6 months to below 6 years.
Amitiza was approved by the U.S.
Food and Drug Administration (FDA) for chronic idiopathic
constipation in adults, irritable bowel syndrome with constipation
in women aged above 18 years and opioid-induced constipation.
Sucampo carries a Zacks Rank #1
(Strong Buy). Investors may also consider companies like
Enanta Pharmaceuticals, Inc. (ENTA), Jazz
Pharmaceuticals (JAZZ) and Questcor
Pharmaceuticals Inc. (QCOR), all of which carry a
comparable Zacks Rank #1.
ENANTA PHARMA (ENTA): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis Report
SUCAMPO PHARMAC (SCMP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024